ITEMS IN AFP WITH KEYWORD:
Find out which lifestyle interventions should be recommended, which medications may be contributing to the problem, and how to choose among the four phosphodiesterase-5 inhibitors currently approved to treat erectile dysfunction.
Feb 15, 2015 Issue
Should Family Physicians Screen for Testosterone Deficiency in Men? No: Screening May Be Harmful, and Benefits Are Unproven [Editorials: Controversies in Family Medicine]
Testosterone testing leads to testosterone treatment, which is inappropriate for the vast majority of patients. Testosterone treatment should be reserved for patients who are truly hypogonadal.
Feb 15, 2015 Issue
Should Family Physicians Screen for Testosterone Deficiency in Men? Yes: Screening for Testosterone Deficiency Is Worthwhile for Most Older Men [Editorials: Controversies in Family Medicine]
With the possible exception of patients with cardiovascular disease, testosterone replacement therapy remains a potentially beneficial option in improving health-related quality of life in men.
Boosting low testosterone levels into the normal range did not further improve the effectiveness of sildenafil in men with erectile dysfunction. The researchers did not determine whether testosterone replacement alone is as effective as sildenafil for the treatment of erectile dysfunction.
As the general population ages and life expectancy increases, erectile dysfunction (ED) is anticipated to be a major health care burden. Therefore, the American College of Physicians (ACP) created a guideline on hormone testing and pharmacologic treatment of ED.
Erectile dysfunction (ED) is the most common sexual problem in men. The incidence increases with age and affects up to one third of men throughout their lives. It causes a substantial negative impact on intimate relationships, quality of life, and self-esteem. History and physical examination are su...
Jan 15, 2006 Issue
AUA Updates Guidelines on Management of Erectile Dysfunction [Practice Guidelines]
The American Urological Association (AUA) has updated its 1996 recommendations on the treatment of erectile dysfunction (ED). ED results from a combination of vascular, neurologic, hormonal, and psychologic factors.
The U.S. Food and Drug Administration (FDA) has approved new label information for erectile dysfunction drugs after reports of sudden vision loss attributed to nonarteritic ischemic optic neuropathy. These drugs include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra).
Like other PDE5 inhibitors, tadalafil effectively improves the ability of men with erectile dysfunction to achieve an erection and successfully complete intercourse. It is less effective, although still useful, in some men with ED due to diabetes. Its longer duration may require less frequent dosing...
Erectile dysfunction, the persistent inability to attain or maintain penile erection sufficient for sexual intercourse, affects millions of men to various degrees. The majority of cases have an organic etiology, most commonly vascular disease that decreases blood flow into the penis. Regardless of t...